Perspective Therapeutics Q4 EPS $(0.04) Down From $(0.01) YoY, Sales $2.09M Down From $2.50M YoY
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics reported Q4 losses of $(0.04) per share, a 300% decrease YoY. The company's sales also decreased by 16.65% to $2.09 million compared to $2.50 million in the same period last year.
August 11, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Perspective Therapeutics' Q4 earnings report shows a significant decrease in EPS and sales YoY.
The significant decrease in both EPS and sales YoY indicates a poor financial performance for Perspective Therapeutics. This is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100